CORTEXA
← Browse
crossrefFrontiers in Pharmacology2026-07-20Cited by 0

Integrating machine learning, deep learning, and docking to predict aristolochic acid A carcinogenesis

Longzhu Li, Jiacheng Liao, Xintian Chen, Zeqiong Lin, Siqiao Gong, Junmin Huang, Ziqian Bi, Tianyang Wang, Xinliang Chia, Lu Chen, Yongzhi Xu, Huafeng Liu, Junfeng Hao, Jiansong Qi

Objective This study investigates the molecular mechanisms of renal clear cell carcinoma (RCC) induced by Aristolochic acid A (AAA) using machine learning, deep learning, and molecular docking approaches. Methods To identify AAA target genes associated with RCC, differential expression analysis was performed on multiple datasets. Network toxicology, machine learning, deep learning, and molecular docking were used to explore the binding interactions between AAA and target proteins. The top candidate gene was validated using molecular dynamics simulation and in vitro Western blot assays. Results A total of 74 genes were identified as potential targets in AAA-induced RCC. Subsequent machine learning analysis identified seven core genes as key regulators of RCC. Deep learning classification further highlighted five of these seven genes, including PYGL, ADH1B, PTGS1, EDNRA, and AURKA. Additionally, molecular docking simulations revealed strong binding affinities between AAA and these target proteins. Molecular dynamics simulation demonstrated the binding stability of the AAA-PYGL complex, and in vitro studies highlighted PYGL as a potential target of AAA. Elevated expression of PYGL was observed in both 786-O and AAA-induced HK-2 cells. Moreover, treatment with CP-91149 (a PYGL inhibitor) or PYGL knockdown restored the expression of E-cadherin, an epithelial-mesenchymal transition (EMT) marker, in HK-2 cells. Conclusion By combining advanced computational methods with in vitro studies, this work elucidates a key toxicity mechanism of AAA in RCC. Our approach provides a feasible and efficient framework for toxicological studies, offering significant value for toxicologists with limited access to clinical specimens.

View free PDFSource page

Related papers

crossrefFrontiers in Pharmacology2026-07-10

Deciphering tuberculosis pathway mechanisms via graph neural networks and multimodal deep learning: a comprehensive AI-driven framework for precision medicine

Yuanli Yang, Huanqing Liu, Qian Lei, Tingting Li

Background Tuberculosis (TB) remains a global health crisis, with complex molecular mechanisms that are not fully understood. Traditional pathway analysis methods fail to capture the intricate non-linear relationships within biological networks. Methods We developed a novel artif…

View free PDFSource page
crossrefFrontiers in Pharmacology2026-07-06

Hybrid mechanistic–machine learning PK/PD models with digital biomarkers: from cage to clinic

Szczepan W. Baran, Stefano Gaburro

Background Pharmacometric PK/PD models remain central to dose selection for first-in-human studies, therapeutic drug monitoring, and animal-to-human extrapolation of exposure–response relationships, but modern datasets, including digital biomarkers from continuous monitoring, omi…

View free PDFSource page
openalexFrontiers in Pharmacology2026-07-24

Editorial: Increasing importance of patients-generated real world data for healthcare policy decisions about medicinal products: volume III

Wai Yee Choon, K C Lee, Paul Scuffham, Shu Chuen Li, David Bin-Chia Wu, Jeff J. Guo

Increasing importance of patient-generated real-world data for healthcare policy decisions about medicinal products: Volume III Real-world data (RWD) and the real-world evidence (RWE) derived from it have moved from the margins to the centre of decision-making about medicinal pro…

View free PDFSource page
openalexFrontiers in Pharmacology2026-07-23

Beyond cardiovascular protection: a conceptual and translational review of the hepato-specific mechanisms of statins in metabolic dysfunction-associated steatotic liver disease (MASLD)

Carolina Jiménez-González, Paula Iruzubieta, Marta Alonso-Peña, Lorena Cayon, Javier Crespo

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, and cardiovascular disease remains the leading cause of death in this population. Statins are therefore a cornerstone of therapy in MASLD because of their antia…

View free PDFSource page
openalexFrontiers in Pharmacology2026-07-23

Polyphyllin II attenuates renal fibrosis in diabetic kidney disease partly through regulation of autophagy and PI3K/AKT/mTOR signaling

Xia Sun, Xinfang Qin, Huixin Bi

Background Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD) worldwide, and renal fibrosis is a key pathological feature driving disease progression. Polyphyllin II (PPII), a steroidal saponin isolated from Rhizoma Paridis, has shown renoprotectiv…

View free PDFSource page
openalexFrontiers in Pharmacology2026-07-24

Indobufen-based dual antiplatelet therapy in patients undergoing PCI: a systematic review and meta-analysis

Yiheng Liu, B Y Liu, Weiran Dai

Background Conventional dual antiplatelet therapy (DAPT) post percutaneous coronary intervention (PCI) comprises aspirin and a P2Y 12 inhibitor. However, aspirin increases gastrointestinal and bleeding risks. Indobufen, a reversible COX-1 inhibitor, may offer a safer alternative.…

View free PDFSource page